This guide is intended to provide the media and other interested stakeholders with sources who are familiar with the latest information in their specialty areas.

The guide is divided into categories based on key disciplines. It contains contact information for experts across the country and a brief description of their specialty areas. If you need additional information or need help identifying the expert who would best serve your needs, please contact ASGT at www.asgt.org or call 414.278.1341.

**Areas of Expertise**
- Arthritis, Muscular Dystrophy and Musculoskeletal Disorders
- Blood Cell Diseases and Anemias
- Cancer
- Cancer Vaccines
- Cardiovascular Disease
- Chronic Pain
- Clinical and Regulatory Issues
- Genetic Diseases
- Infectious Disease and Gene Vaccines
- Neuro-degenerative and Movement Disorders
- Oligonucleotide-based Therapeutics
- Respiratory and Cystic Fibrosis
- Tissue Engineering
- Vector Technology
- Vision Disorders

**Gene Therapy**
Gene therapy is the process of inserting nucleic acids (e.g. usually DNA/genes) into cells or tissues to correct or prevent a pathological process. Examples include the gene addition for the treatment of genetic disorders as well as therapeutic nucleic acids to stimulate new cell growth for tissue regeneration, demise of cancerous and virus infected cells.

**American Society of Gene Therapy**
The American Society of Gene Therapy (ASGT) is a professional non-profit medical and scientific organization dedicated to the understanding, development and application of gene and related cell and nucleic acid therapies and the promotion of professional and public education in the field. ASGT is the largest medical professional organization representing researchers and scientists dedicated to discovering new gene therapies.

ASGT’s goals are to promote research, development and application of gene therapy to treat diseases in society and provide education on gene therapy to the public.

For more information on ASGT and gene therapy, visit www.asgt.org

**About this Guide**
ASGT’s nearly 3,000 members are experts in a wide variety of disciplines, from cardiovascular and blood cell diseases to vector technology and vaccines. Vector technology involves the transport of genetically altered DNA into cells.
Dr. Paul D. Robbins, Ph.D.

University of Pittsburgh
Department of Molecular Genetics and Biochemistry
W1246 Biomedical Science Tower
Pittsburgh, PA 15261

Ph: (412) 648-9268
Fax: (412) 383-8837
probb@pitt.edu

Dr. Robbins is Director of Basic Research at the Institute for Molecular Medicine at the University of Pittsburgh School of Medicine. He is also a Professor in the departments of Molecular Genetics and Biochemistry and Orthopaedic Surgery there. Since 2003, Robbins has served as Co-Director of the Paul Wellstone Cooperative Center of Excellence in Muscular Dystrophy. He received his undergraduate training at Haverford College in Pennsylvania and his Ph.D. at the University of California, Berkeley.

Dr. Helen Heslop, M.D.

Baylor College of Medicine
6621 Fannin Street, MC 3-3320
Houston, TX 77030

Ph: (832) 824-4662
Fax: (832) 825-4668
hheslop@bcm.tmc.edu

Dr. Heslop is Director of the Adult Stem Cell Transplant Program in the Center for Cell and Gene Therapy. Her research interests are in augmenting anti-viral and anti-tumor immunity following transplant. She is an editor of the journal Bone Marrow Transplantation and holds a Doris Duke Distinguished Clinical Scientist Award.
Dr. Donald B. Kohn, M.D.

Childrens Hospital Los Angeles
Research Immunology/BMT
4650 Sunset Blvd., #62
Los Angeles, CA 90027

Ph: (323) 669-4617
Fax: (323) 667-1021
E-mail: dkohn@chla.usc.edu

Dr. Kohn is Professor of Pediatrics, and Molecular Microbiology & Immunology in the University of Southern California Keck School of Medicine. He is the Head of the Division of Research Immunology/Bone Marrow Transplantation and Director of the Gene, Immune and Stem Cell Therapy in the Saban Research Institute of Childrens Hospital Los Angeles. Kohn’s research program performs basic, pre-clinical and clinical studies of gene therapy using hematopoietic cells for genetic diseases and AIDS. He has been the recipient of numerous awards, including the Elizabeth Glaser Pediatrics AIDS Foundation Scholar Award, a Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation, and was President of the American Society of Gene Therapy (2003-2004). Kohn received his M.D. at the University of Wisconsin and completed his residency at the University of Wisconsin Hospital in Madison.

Dr. Arthur W. Nienhuis, M.D.

St. Jude Children’s Research Hospital
332 N. Lauderdale Street
Memphis, TN 38105

Ph: (901) 495-4266
Fax: (901) 525-2720
Arthur.nienhuis@stjude.org

Dr. Nienhuis is a full member of the faculty in the Division of Experimental Hematology at St. Jude Children's Research Hospital, having previously served as Director and Chief Executive Officer. Previously, he was Chief of the Clinical Hematology Branch in the Intramural Program of the National Heart, Lung, and Blood Institute at the National Institutes of Health. His research is focused on the development of gene therapy for the treatment of blood disorders, most specifically, sickle cell anemia, thalassemias, and immunodeficiencies.
<table>
<thead>
<tr>
<th><strong>Dr. John J. Nemunaitis, M.D.</strong></th>
<th><strong>Dr. Michel Sadelain, M.D., Ph.D.</strong></th>
</tr>
</thead>
</table>
| Mary Crowley Medical Research Center  
1717 Main Street, 60th floor  
Dallas, TX 75201 | Memorial Sloan-Kettering Cancer Center  
1275 York Avenue, Room S1014  
New York, NY 10021 |
| Ph: (214) 658-1964  
Fax: (214) 658-1992  
nemunaitis@mcmrc.com | Ph: (212) 639-6190  
Fax: (917) 432-2340  
sadelain@ski.mskcc.org |

Dr. Nemunaitis has served as Executive Director of the Mary Crowley Research Center since 1995. Prior to this position, Nemunaitis was Research Director at Texas Oncology, P.A. for more than ten years, and Director of the Hematopoiesis Program at the Western Pennsylvania Cancer Institute. He also served as Assistant Professor of Medicine at the University of Washington, and is the author of 206 peer review publications and 31 book chapters. Nemunaitis received his medical degree at Case Western Reserve University and trained as a resident at Boston City Hospital.

Dr. Sadelain is the Director of Gene Transfer and Somatic Cell Engineering Facility and the Head of Gene Transfer and Gene Expression Laboratory at Memorial Sloan-Kettering Cancer Center. His clinical expertise is in gene transfer and genetic therapies, congenital and acquired disorders of the Hematopoietic and Immune Systems, and Immunotherapy. Sadelain received his M.D. from the University of Paris and his Ph.D. from the University of Alberta.
**Dr. Savio L.C. Woo, Ph.D.**

Mount Sinai School of Medicine  
Department of Gene and Cell Medicine  
One Gustave Levy PL # 1496  
New York, NY 10029  

Ph: (212) 659-8260  
F: (212) 849-2572  
Savio.woo@mssm.edu

A widely recognized expert in molecular biology, human genetics, cell and gene therapy, Dr. Woo has been a Professor and Founding Chairman of the Department of Gene and Cell Medicine at the Mount Sinai School of Medicine in New York City since 1996. His research focuses on science and technology development in gene and cell therapies for metabolic disorders and cancer, as well as clinical translation of laboratory advances into direct patient care. Woo was a founding Board member (1996–1999) and a member of the Advisory Board (2000–2005) of the American Society of Gene Therapy (ASGT), and served as its third President (1999–2000). He was the founding director of a comprehensive review course for clinical gene transfer (2000–2003) to facilitate translational research, which was co-sponsored by the ASGT, FDA, NIH and OHRP.

**Dr. Drew Pardoll, M.D., Ph.D.**

John Hopkins University School of Medicine  
1650 Orleans Street, CRB 440  
Baltimore, MD 21205  

Ph: (410) 955-7866  
Fax: (410) 614 0579  
dmpardol@jhmi.edu

Dr. Pardoll is Professor of Medicine, Pathology and Molecular Biology and Genetics at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He holds the Seraph Chair of Oncology and is Director of the Cancer Immunology Program and the Division of Immunology and Hematopoiesis in the Department of Oncology at the Johns Hopkins School of Medicine. Pardoll was among the first scientists to develop genetically engineered cancer vaccines, and is the recipient of numerous awards, including the Cancer Research Institute Investigators Award and the Burroughs Wellcome Experimental Therapeutics Award. Pardoll received his M.D. and Ph.D. from The Johns Hopkins University.
Dr. David A. Dichek, M.D.

University of Washington
1959 NE Pacific St., Box 357710
Seattle, WA 98195

Ph: (206) 685-6959
Fax: (206) 221-6346
ddichek@u.washington.edu

Dr. Dichek is a board-certified, practicing cardiologist and a laboratory-based investigator. He has worked to develop cardiovascular gene therapy since 1988. Dichek obtained his M.D. from UCLA, trained as a resident in internal medicine at Massachusetts General Hospital, and as a cardiologist at the National Institutes of Health and the Johns Hopkins Hospital. Since 2001, he holds the John Locke Family Endowed Chair in Cardiovascular Research and Treatment at the University of Washington, where he is Professor of Medicine and Associate Director for Research in the Division of Cardiology.

Dr. Roger J. Hajjar, M.D.

Massachusetts General Hospital
Cardiovascular Research Center
149 13th Street, 4th floor, Room 4215
Charlestown, MA 02129

Ph: (617) 726-3748
Fax: (617)726-5806
rhajjar@partners.org

Dr. Hajjar is Associate Professor of Medicine at Harvard Medical School and staff cardiologist in the Heart Failure & Cardiac Transplantation Center at Massachusetts General Hospital. He is also Director of the Cardiology Laboratory of Integrative Physiology & Imaging at Massachusetts General Hospital. Hajjar has won numerous awards and distinctions, including the Young Investigator Award of the American Heart Association. He received his M.D. from Harvard Medical School and trained in Internal Medicine and Cardiology at Massachusetts General Hospital in Boston.
Dr. Joseph Glorioso, Ph.D.
University of Pittsburgh School of Medicine
Dept. Molecular Genetics/Biochemistry
Pittsburgh, PA, 15261
Ph: (412) 648-8105
Fax: (412) 624-8997
glorioso@pitt.edu

Dr. Losordo is the Chief Cardiovascular Research Professor of Medicine at Tufts University. He also served as the Director of Cardiac Catheterization Laboratories at St. Elizabeth's Medical Center in Boston from 2000-2004 and worked as a staff physician at the Division of Cardiovascular Medicine and Research Center in Boston. Losordo currently serves on the editorial board of the Journal of the American College of Cardiology, Circulation, and Circulation Research. He received his B.A. and M.D. from the University of Vermont and a degree in Molecular Biology from the Cold Spring Harbor Laboratories.

Dr. Glorioso is a Professor and Chairman of the Department of Molecular Genetics & Biochemistry at the University of Pittsburgh. Glorioso also holds the McEllroy Professorship in Biochemistry, and he is the Director of the Human Gene Therapy Center at the University of Pittsburgh, a position he has held since the formation of the Center in 1990. In addition, he currently co-directs a Juvenile Diabetes Foundation Center and is Associate Director for the Center for Cell Therapeutics. Glorioso received his bachelor’s degree and doctorate from Louisiana State University.
Dr. Katherine A. High, M.D.

University of Pennsylvania School of Medicine
302 Abramson Research Center
3615 Civic Center Boulevard
Philadelphia, PA 19104-4399
Ph: (215) 590-4521
Fax: (215) 950-3660
high@email.chop.edu

Dr. High is a William H. Bennett Professor of Pediatrics, Investigator of Howard Hughes Medical Institute, and Director of the Center for Cellular and Molecular Therapeutics. Her research interests have focused on the molecular basis of blood coagulation and involve the characterization of mutations that cause hemophilia, and structure-function studies and gene expression analysis of factors involved in the coagulation process. More recently, her work has focused on development of novel therapeutics for hemophilia. She graduated from Harvard with a degree in Chemistry and received her M.D. at the University of North Carolina (UNC) School of Medicine. High is an active member and Councillor of the American Society of Hematology, serves on the National Heart, Lung, and Blood Institute Advisory Council, and is the immediate Past President of the American Society of Gene Therapy.

Dr. Daniel Salomon, M.D.

The Scripps Research Institute
10550 N. Torrey Pines Rd MEM-241
La Jolla, CA 92037
Ph: (858) 784-9381
Fax: (858) 784-2121
dsalomon@scripps.edu

Dr. Salomon is an Associate Professor at The Scripps Research Institute (TSRI) in the Department of Molecular and Experimental Medicine. He is the Director of the Center for Organ and Cell Transplantation for Scripps Health at Scripps Green Hospital. Salomon is presently the Chair of the Steering Committee of the NIH National Islet Cell Resource Consortium, Chair of the American Society of Transplantation Cell Transplantation Committee, Chair of the American Society of Gene Therapy’s Clinical and Regulatory Affairs Committee and a member of the NIH Transplantation, Tolerance and Tumor Immunology Study Section. His undergraduate training was at Northwestern University and he received his M.D. at the Stritch-Loyola School of Medicine.
**Clinical and Regulatory Issues**

**Dr. Savio L.C. Woo, Ph.D.**

Mount Sinai School of Medicine  
Department of Gene and Cell Medicine  
One Gustave Levy PL # 1496  
New York, NY 10029  
Ph: (212) 659-8260  
Fax: (212) 849-2572  
Savio.woo@mssm.edu

A widely recognized expert in molecular biology, human genetics, cell and gene therapy, Dr. Woo has been a Professor and Founding Chairman of the Department of Gene and Cell Medicine at the Mount Sinai School of Medicine in New York City since 1996. His research focuses on science and technology development in gene and cell therapies for metabolic disorders and cancer, as well as clinical translation of laboratory advances into direct patient care. Woo was a founding Board member (1996–1999) and a member of the Advisory Board (2000–2005) of the American Society of Gene Therapy (ASGT), and served as its third President (1999–2000). He was the founding director of a comprehensive review course for clinical gene transfer (2000–2003) to facilitate translational research, which was co-sponsored by the ASGT, FDA, NIH and OHRP.

**Dr. Theodore Friedmann, M.D.**

UCSD School of Medicine  
CMG 0634 Peds.  
9500 Gilman Drive  
La Jolla, CA 92093-0634  
Ph: (858) 534-4268  
Fax: (858) 534-1422  
tfriedmann@ucsd.edu

Dr. Friedmann is Professor of Pediatrics at the UCSD School of Medicine and Director of the UCSD Program in Human Gene Therapy. He is the 2006-2007 President of the American Society of Gene Therapy. He holds leadership posts on several committees, serving as Chairman of the Recombinant DNA Advisory Committee of the NIH and the Advisory Committee for Germ-line Gene Therapy at AAAS. Friedmann also serves as a member of the IOC, WADA, Committee of Medicine, Health and Research and the US Anti-Doping Agency. From 2000-2002 he was a member of the Advisory Committee on Human Cloning for the state of California. Friedmann received his undergraduate training and M.D. at the University of Pennsylvania, and has published more than 200 journal articles since 1992.
Dr. Mark A. Kay, M.D., Ph.D.

Stanford University School of Medicine
Depts. of Pediatrics and Genetics
300 Pasteur Dr., RM G-305A
Stanford, CA 94305-5208

Ph: (650) 498-6531
Fax: (650) 498-6540
markay@stanford.edu

Dr. Kay is the Director of the Program in Human Gene Therapy and a Professor in the Departments of Pediatrics and Genetics at Stanford University School of Medicine. He was on the founding board of directors of the American Society of Gene Therapy and served as President in 2005-2006. Previously, Kay was at the University of Washington as Associate Professor in the Departments of Medicine, with adjuncts in Pediatrics, Biochemistry and Pathology. His research has led to more than 150 scientific publications in various leading journals. Kay has a Ph.D. in Developmental Genetics and M.D. from Case Western Reserve in Cleveland, Ohio.

Dr. Katherine Ponder, M.D.

Washington University School of Medicine
Division of Hematology
660 S Euclid Ave. Box 8125
St. Louis, MO 63110

Ph: (314) 362-5188
Fax: (314) 362-8813
kponder@im.wustl.edu

Dr. Ponder is Associate Professor in the Division of Hematology at the Washington University School of Medicine. Her clinical interest is in hemostasis and her research interests include gene therapy for blood protein deficiencies, liver regeneration, and liver-specific function. Ponder is a member of the National Hemophilia Foundation Medical and Scientific Advisory Council. She received her M.D. at Washington University in St. Louis and was a postdoctoral associate at Yale University and Baylor Medical College.
Dr. Ronald Crystal, M.D.

Weill Medical College, Cornell University
New York, NY, 10021

Ph: (212) 746-2258
Fax: (212) 746-8383
rgcryst@med.cornell.edu

Dr. Crystal is Professor and Chairman of the Department of Genetic Medicine of the Weill Medical College of Cornell University, where he is also the Bruce Webster Professor of Internal Medicine, Director of the Belfer Gene Therapy Core Facility and Chief of the Division of Pulmonary and Critical Care Medicine at the Weill Cornell-New York Presbyterian Hospital. Prior to moving to Cornell, Crystal joined the National Institutes of Health, where he served as Chief of the Pulmonary Branch of the National Heart, Lung and Blood Institute. He is responsible for numerous biomedical patents and is the founder of GenVec, a biomedical company focused on gene therapy applications. Crystal received his M.S. and M.D. degrees from the University of Pennsylvania.

Dr. John A. Zaia, M.D.

City of Hope National Medical Center
Beckman Research Institute
1500 E. Duarte Rd.
Famillian/BMT Building
Duarte, CA 91010-3000

Ph: (626) 471-7149
Fax: (626) 423-5881
jzaia@bricoh.org

Dr. Zaia has been the chairman of Virology and Infectious Diseases, Division of Pediatrics at the City of Hope National Medical Center since 1980. He also serves as Professor of the Department of Pediatrics, Chairman of the Gene Therapy Advisory Committee, Director of the Strategic Program for Innovative Research in AIDS, and IRB chairman—all positions which are based at the City of Hope National Medical Center. Zaia is the Director of the General Clinical Research Center of the University of Southern California School of Medicine and Associate Director of the University of Southern California General Clinical Research Center, City of Hope GCRC Satellite. He received his M.D. from Harvard University.
Dr. Xandra Breakefield, Ph.D.

Massachusetts General Hospital
Molecular Neurogenetics
Bldg 149 13th St. Room 6203
Charlestown, MA 02129

Ph: (617) 726-5728
Fax: (617) 724-1537
breakefield@hms.harvard.edu

Dr. Breakefield is a geneticist in the Neurology and Radiology Services at Massachusetts General Hospital where she directs the Laboratory of Experimental Gene Therapy. She is also currently a Professor of Neurology in the Neuroscience Program at Harvard Medical School and previously served as Associate Professor and Professor at the Human Genetics Department at Yale University School of Medicine. Breakefield received her Ph.D. in Microbial Genetics from Georgetown University.

Dr. Beverly L. Davidson, Ph.D.

University of Iowa College of Medicine
200 EMRB
200 Newton Road
Iowa City, IA 52242

Ph: (319) 353-5511
Fax: (319) 353-5572
Beverly-davidson@uiowa.edu

Dr. Davidson is the Director of the Gene Transfer Vector Core at the University of Iowa. She also serves as a Professor in the Departments of Internal Medicine, Neurology, Physiology and Biophysics, and as a member of the Neuroscience, Molecular Biology, and Genetics graduate degree training programs at the University of Iowa. Since 1999 she has served as the Roy J. Carver Biomedical Research Chair in Internal Medicine at the University of Iowa. Davidson is a member of the National Gene Vector Laboratory Scientific Review Board and a member of the Scientific Committee for Neuromuscular Disorders at the American Society of Gene Therapy. Davidson received her Ph.D. from the University of Michigan and performed post-doctoral work at the school on molecular genetics.
Dr. John H. Wolfe, VMD, Ph.D.

Childrens Hospital of Philadelphia
Dept. of Neurology, Pediatrics
502 Abramson Bldg, 3516 Civic Center Blvd
Philadelphia, PA 19104

Ph: (215) 590-7028
Fax: (215) 590-3779
jhwolfe@vet.upenn.edu

Dr. Wolfe is Professor of Pathology in the Department of Pathobiology in the School of Veterinary Medicine at the University of Pennsylvania. He is also Professor of Pathology and Medical Genetics in Pediatrics in the School of Medicine there, in addition to serving as Stokes Investigator of the Joseph Stokes, Jr. Research Institute at the Children’s Hospital of Philadelphia. He is a member of numerous societies, including the American Society of Human Genetics, the American Society of Microbiology and the Society for Neurosciences. Wolfe received his V.M.D and Ph.D. at the University of Pennsylvania.

Dr. Mark A. Kay, M.D., Ph.D.

Stanford University School of Medicine
Depts. of Pediatrics and Genetics
300 Pasteur Dr., RM G-305A
Stanford, CA 94305-5208

Ph: (650) 498-6531
Fax: (650) 498-6540
markay@stanford.edu

Dr. Kay is the Director of the Program in Human Gene Therapy and a Professor in the Departments of Pediatrics and Genetics at Stanford University School of Medicine. He was on the founding board of directors of the American Society of Gene Therapy and served as President in 2005-2006. Previously, Kay was at the University of Washington as Associate Professor in the Departments of Medicine, with adjuncts in Pediatrics, Biochemistry and Pathology. His research has led to more than 150 scientific publications in various leading journals. Kay has a Ph.D. in Developmental Genetics and M.D. from Case Western Reserve in Cleveland, Ohio.
Dr. John J. Rossi, Ph.D.

Beckman Research Institute, City of Hope
Division of Molecular Biology
1450 E. Duarte Rd.
Duarte, CA 91010

Ph: (626) 301-8390
Fax: (626) 301-8271
jrossi@coh.org

Dr. Rossi is Chairman and Professor of Molecular Biology at the Beckman Research Institute at the City of Hope in Duarte, California and began his work there in 1980. His initial studies involved uses of synthetic DNA for studies of gene regulation, and in 1986 his research program moved in part to studies of HIV infection. At present, a large percentage of his lab’s research is focused upon the biology and utilization of small interfering RNAs. Rossi received his doctorate in 1976 in Microbial Genetics at the University of Connecticut, and his postdoctoral training at Brown University Medical School.

Dr. Bruce Sullenger, Ph.D.

Duke University Medical Center
421 MSRB, Box 2601
Durham, NC 27710

Ph: (919) 684-6375
Fax: (919) 684-6492
b.sullenger@cgct.duke.edu

Dr. Sullenger is a Professor in the Chief Division of Experimental Surgery and Director of the Duke Center for Translational Research at the Duke University Medical Center. He is also a Professor in the Department of Surgery. Sullenger has received several top honors throughout his career, including being awarded the Ruth & A. Morris Williams, Jr. Faculty Research Prize at Duke, the Joseph and Dorothy Beard Endowed Chair in Experimental Surgery, and the Azure De Ellis Research Award for Sickle Cell Research. He received his undergraduate degree at Indiana University, Bloomington, and his Ph.D. at Cornell University.
Dr. John F. Engelhardt, Ph.D.

University of Iowa
Room 1-111 Bowen Science Building
51 Newton Rd.
Iowa City, IA 52212-1109
Ph: (319) 335-7744
Fax: (319) 335-7770
John-engelhardt@uiowa.edu

Dr. Engelhardt is Professor and Interim Chair of the Department of Anatomy and Cell Biology at the University of Iowa, and a Professor in the Department of Internal Medicine. His research focuses on using gene therapy to treat cystic fibrosis and other respiratory diseases. Since 1998 he has served as Director of the Center for Gene Therapy of Cystic Fibrosis and Other Genetic Diseases, and was named the Roy J. Carver Chair in Molecular Medicine at the University of Iowa in 2004. Engelhardt was elected to the Board of Directors of the American Society of Gene Therapy in 2003, and received the NIH Merit Award (NIDDK) in 2005.

Dr. Darwin J. Prockop, M.D., Ph.D.

TUHSC Center for Gene Therapy
1430 Tulane Ave., Sl-99
New Orleans, LA 70112-2699
Ph: (504) 988-7711
Fax: (504) 988-7710
dprocko@tulane.edu

Dr. Prockop is Professor of Biochemistry and Director of the Center for Gene Therapy at Tulane University Health Sciences Center. Prockop conducts research on the biosynthesis of collagen, structure and function of collagen genes, and genetic mutations that cause diseases of bone and cartilage. He has received many prestigious honors, including being elected to the National Academy of Sciences and the Institute of Medicine, and receiving the Lee C. Howley Prize of the Arthritis Foundation for research on arthritis. He received his M.D. from the University of Pennsylvania, and earned his Ph.D. from the George Washington University.
Dr. Mervin Yoder, M.D.

Cancer Research Institute
Indiana University School of Medicine
1044 W Walnut
Indianapolis, IN 46202

Ph: (317) 274-4719
Fax: (317) 274-8679
myoder@iupui.edu

Dr. Yoder is Professor of Pediatrics and of Biochemistry and Molecular Biology at the Indiana University School of Medicine in Indianapolis. His areas of expertise include molecular regulation of hematopoiesis in the murine embryo, changes in hematopoietic stem cell biology with ontogeny and the role of the microenvironment in regulating hematopoietic stem cell function. He served as the Richard and Pauline Klingier Professor of Pediatrics Endowed Chair in 2003 and has received honors from the American Pediatric Association and the Perinatal Research Society. Yoder received his M.D. from the Indiana University School of Medicine.

Dr. David Curiel, M.D., Ph.D.

University of Alabama at Birmingham
Gene Therapy Center
901 19th Street, Rm. 502
Birmingham, AL 35294-2172

Ph: (205) 934-8627
Fax: (205) 975-7476
curiel@uab.edu

Dr. Curiel heads the Gene Therapy Center (GTC) of the University of Alabama at Birmingham. He is Director of the Division of Human Gene Therapy, which is affiliated with the Departments of Medicine, Pathology and Surgery. Curiel received his M.D. from Emory University in 1982 where he also completed his internship and residency in Internal Medicine. Dr. Curiel’s scientific training includes tenureship at the National Institutes of Health, at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI) from 1985-1989, a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990.
**Dr. Mark A. Kay, M.D., Ph.D.**

Stanford University School of Medicine  
Depts. of Pediatrics and Genetics  
300 Pasteur Dr., RM G-305A  
Stanford, CA 94305-5208  

Ph: (650) 498-6531  
Fax: (650) 498-6540  
markay@stanford.edu  

Dr. Kay is the Director of the Program in Human Gene Therapy and a Professor in the Departments of Pediatrics and Genetics at Stanford University School of Medicine. He was on the founding board of directors of the American Society of Gene Therapy and served as President in 2005-2006. Previously, Kay was at the University of Washington as Associate Professor in the Departments of Medicine, with adjuncts in Pediatrics, Biochemistry and Pathology. His research has led to more than 150 scientific publications in various leading journals. Kay has a Ph.D. in Developmental Genetics and M.D. from Case Western Reserve in Cleveland, Ohio.

**Dr. Inder M. Verma, Ph.D.**

Salk Institute, Laboratory of Genetics  
10010 N. Torrey Pines Rd.  
La Jolla, CA 92037  

Ph: (858) 453-4100  
Fax: (858) 558-7454  
verma@salk.edu  

Dr. Verma has been Professor in the Laboratory of Genetics at the Salk Institute since 1985, and an Adjunct Professor at the Department of Biology at the University of California, San Diego since 1983. He has received numerous honors, including being elected to the American Academy of Arts and Sciences in 2000, the Institute of Medicine in 1999, and the National Academy of Sciences in 1997. Verma received his undergraduate degree at Lucknow University in India, and his Ph.D. at The Weizmann Institute in Rehovot, Israel. He also received a Postdoc degree at M.I.T in Biology.
Dr. Jean Bennett, M.D., Ph.D.

University of Pennsylvania Scheie Eye Institute
310 Stellar-Chance Labs
422 Curie Blvd.
Philadelphia, PA, 19104-6069

Ph: (215) 898-0915
Fax: (215) 573-7155
jebennet@mail.med.upenn.edu

Dr. Bennett is a Professor of Ophthalmology, Cell and Developmental Biology at the University of Pennsylvania. Her research interests include molecular genetics of retinal degenerations and gene therapy-mediated treatment of ocular disease. Bennett has developed a number of strategies for gene therapy-mediated treatments for retinal disease. She received her Ph.D. from the University of California, Berkeley, and her M.D. from Harvard Medical School.